Altered amyloid plasma profile in patients with disabling headaches after SARS-CoV-2 infection and vaccination.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aamodt Anne Hege, Ueland Thor, Boldingh Marion, Bezgal Burcu Ella, Argren Maria Bengtson, Dunne Cecilia Adele, Otterdal Kari, Gregersen Ida, Bjerkeli Vigdis, Michelsen Annika Elisabet, Husøy Andreas, Morsund Åse Hagen, Devik Kristina, Poole Anne Christine, Gjendemsjø Kristine Bodding, Schlüter Katrin, Mathisen Sara Maria, Aalstad-Johansen Mari, Skattør Thor Håkon, Sønnervik Julie, Boye Turid Birgitte, Popperud Trine Haug, Høgestøl Einar August, Harbo Hanne Flinstad, Lund-Johansen Fridtjof, Aukrust Pål, Tronvik Erling, Dahl Tuva Børresdatter, Halvorsen Bente Evy
Аннотация
METHODS: In this prospective observational cohort, patients presenting with severe headache as the dominating symptom after COVID-19 (n=29) or SARS-CoV-2 vaccination (n=31) had neurological assessments with reassessments after 6 months. Plasma levels of amyloid precursor protein (APP), pregnancy zone protein (PZP), cathepsin L1 (CTSL) and serum Amyloid A (SAA1) were measured using ELISA and compared with levels in healthy controls (n=16).
RESULTS: We found a strong and persistent upregulation of APP in patients with headache after COVID-19 as compared with the two other groups. Notably, APP levels remained elevated at both inclusion and after 6 months in individuals with accompanying cognitive symptoms. In contrast, PZP levels were increased in patients with headache after SARS-CoV-2 vaccination at both time points relative to healthy controls. CTSL was only elevated in the post-COVID-19 at baseline, whereas SAA1 showed levels comparable across all groups.
CONCLUSION: Altered plasma levels of soluble markers, potentially reflecting changes in amyloid processing, were found in patients with persistent headache following SARS-CoV-2 vaccine, particularly in those with persistent headache after COVID-19. In the latter group, we also found some association with cognitive symptoms.
TRIAL REGISTRATION NUMBERS: NCT04576351 and NCT05235776.